Caris Life Sciences Presented Research Demonstrating the Value of Whole Transcriptome Sequencing in Precision Oncology at the Association of Molecular Pathology 2026 Annual Meeting
PR Newswire
IRVING, Texas, Nov. 16, 2026
Two Caris-led studies highlight the power of comprehensive RNA sequencing to identify novel and rare gene fusions across solid tumors
IRVING, Texas, Nov. 16, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that Caris and collaborators presented two posters at the Association for Molecular Pathology (AMP) 2026 Annual Meeting. The research demonstrates how Caris' comprehensive Whole Transcriptome Sequencing (WTS) and clinico-genomic data are redefining fusion discovery by uncovering novel and rare gene fusions. It also assesses outcomes with matched therapies and reveals clinically meaningful molecular insights that can advance precision oncology and targeted therapy.
The two Caris-led studies investigate gene fusions across gynecologic serous carcinoma and a broad pan-cancer cohort, with WTS-based outcome analyses in non-small cell lung cancer (NSCLC) and cholangiocarcinoma. Among the research, a large-scale analysis of 698,406 solid tumors used WTS to investigate novel gene fusions and evaluate outcomes associated with matched therapies, while a second study characterized rare PAK-family gene fusions in ovarian, fallopian tube and primary peritoneal serous carcinomas. The studies highlight the breadth of molecular insights that can be generated through comprehensive RNA-based profiling and its potential to identify clinically meaningful alterations that may otherwise remain unrecognized.
"Gene fusions can be important drivers of cancer, but identifying the full spectrum of these alterations requires a comprehensive view of the tumor," said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. "By applying WTS across a dataset of this scale, we can uncover new and rare fusions, better understand their clinical significance and generate insights that can help advance precision oncology."
Caris-Led Studies
Posters:
Whole Transcriptome Sequencing Identifies Novel Clinically Actionable Gene Fusions Across 698,406 Solid Tumors with Comparable Outcomes to Canonical Fusion Partners
Authors: Joe Murray, James Hamrick, Jaclyn Hechtman, Paul Campitelli, Andrew Hinton, Rebecca Feldman, Matthew Oberley, Alexander Drilon, Emily K. Bergsland, Christian Rolfo, Mihaela Aldea, James Cleary, Stephen V. Liu, Hossein Borghaei, Balazs Halmos, Moh'd Khushman, Shaheenah Dawood, Daniel Magee, David Spetzler
Key Findings
- WTS detected fusion transcripts in 503,460 of 698,406 solid tumors (72.1%), with more than 34,000 tumors having fusions classified as clinically significant.
- More than 91% of the actionable fusion pairs identified were not previously listed in the reference databases used in the study.
- In linked claims analyses, patients with novel and canonical ALK or FGFR2 fusions who received matched TKIs had comparable survival; both groups had longer survival than patients who received non-TKI treatments.
The findings demonstrate the power of Caris' WTS and clinico-genomic data to expand fusion discovery beyond established reference databases and generate clinical evidence supporting the relevance of newly identified actionable fusion partners.
Detection of PAK Family Gene Fusions in Serous Carcinoma of Ovary, Fallopian Tube, and Peritoneum
Authors: Sachein Sharma, Kristy Lee, Cristina Ramirez, Bryan Krock, Jaclyn F. Hechtman, Matthew J. Oberley, Lulu Sun, Mark G. Evans.
Key Findings
- PAK1, PAK2, or PAK3 fusions were found in 237 tumors – 0.17% of the ovarian, fallopian tube and primary peritoneal serous carcinoma tumors studied.
- The fusions had a range of gene partners - DLG1 and GAB2 were the most common - and retained the part of the PAK genes that make the kinase protein.
- The identification of these rare fusions, which appeared in both high-grade and borderline/low-grade serous carcinomas, may help guide future research as targeted approaches develop.
The findings expand understanding of rare PAK-family gene fusions in gynecologic serous carcinomas and demonstrate how Caris' comprehensive molecular profiling, including WTS, can identify and characterize uncommon molecular alterations for future precision oncology and targeted-therapy research.
Full abstracts are available on the Caris website.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: continued development, performance and commercialization of Caris Detect and Caris Confirm; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions, including the effect of legislative, regulatory, or administrative actions on reimbursement; the impact on our future volumes of the continued execution of our strategy to re-align and expand our sales organization; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-presented-research-demonstrating-the-value-of-whole-transcriptome-sequencing-in-precision-oncology-at-the-association-of-molecular-pathology-2026-annual-meeting-302939983.html
SOURCE Caris Life Sciences
